Start the conversation
5/19/15: This afternoon, Valeant Pharmaceuticals International (NYSE: VRX) will hold its annual general meeting. Investors are expected to ask company CEO Mike Pearson whether the firm will pursue another acquisition in 2015. The company recently won a bidding war for Endo International Plc. (Nasdaq: ENDO) in March, after it failed to acquire Botox-maker Allergan Inc. (NYSE: AGN) last year. Recently, activist investor Bill Ackman compared Valeant to an "early-stage Berkshire Hathaway" (NYSE: BRK.A), arguing the company will provide immense investor value through acquisitions in the years to come.